Implications of NADIA on 2nd line ART regimens

Local and international guidelines recommend second-line regimen including DTG + 2 NRTIs. If TDF/FTC was first-line NRTI backbone, then the recommend NRTI switch is to 3TC/ZDV. The NADIA trial supports use of DTG + 2 NRTIs as second-line ART, even if NRTIs are predicted to have no activity, but resistance is a concern. Join this webinar with Dr Jeremy Nel as we unpack the implications of NADIA trial results on 2nd line ART regimens. Presenter: Dr Jeremy Nel – Physician, Infectious Diseases Specialist